Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
Journal of Biomolecular Screening
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
1087057108326536v1
13/10/999    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (3)
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Engeloch, C.
Right arrow Articles by Popov, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Engeloch, C.
Right arrow Articles by Popov, M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Stability of Screening Compounds in Wet DMSO

Caroline Engeloch

Lead Finding Platform/Novartis Compound Archive, Novartis Institutes for BioMedical Research, Basel, Switzerland, Caroline.Engeloch{at}novartis.com

Ulrich Schopfer

Lead Finding Platform/Novartis Compound Archive, Novartis Institutes for BioMedical Research, Basel, Switzerland

Ingo Muckenschnabel

Analytical Sciences, Novartis Institutes for BioMedical Research, Basel, Switzerland

Francois Le Goff

Analytical Sciences, Novartis Institutes for BioMedical Research, Basel, Switzerland

Hervé Mees

Lead Finding Platform/Novartis Compound Archive, Novartis Institutes for BioMedical Research, Basel, Switzerland

Karoline Boesch

Lead Finding Platform/Novartis Compound Archive, Novartis Institutes for BioMedical Research, Basel, Switzerland

Maxim Popov

Lead Finding Platform/Molecular and Library Informatics, Novartis Institutes for BioMedical Research, Basel, Switzerland

The impact of storage conditions on compound stability and compound solubility has been debated intensely over the past 5 years. At Novartis, the authors decided to opt for a storage concept that can be considered controversial because they are using a DMSO/water (90/10) mixture as standard solvent. To assess the effect of water in DMSO stocks on compound stability, the authors monitored the purity of a subset of 1404 compounds from ongoing medicinal chemistry projects over several months. The study demonstrated that 85% of the compounds were stable in wet DMSO over a 2-year period at 4 °C. This result validates the storage concept developed at Novartis as a pragmatic approach that takes advantage of the benefits of DMSO/water mixtures while mediating the disadvantages. In addition, the authors describe how purity data collected over the course of the chemical validation of high-throughput screening actives are used to improve the analytical quality of the Novartis screening deck. (Journal of Biomolecular Screening 2008:999-1006)

Key Words: compound management • storage conditions • wet DMSO • high-throughput liquid chromatography/mass spectroscopy (HT LC/MS) • quality control (QC)

This version was published on December 1, 2008

Journal of Biomolecular Screening, Vol. 13, No. 10, 999-1006 (2008)
DOI: 10.1177/1087057108326536


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
J Biomol ScreenHome page
Z. Blaxill, S. Holland-Crimmin, and R. Lifely
Stability Through the Ages: The GSK Experience
J Biomol Screen, June 1, 2009; 14(5): 547 - 556.
[Abstract] [PDF]


Home page
J Biomol ScreenHome page
R. MacArthur, W. Leister, H. Veith, P. Shinn, N. Southall, C. P. Austin, J. Inglese, and D. S. Auld
Monitoring Compound Integrity With Cytochrome P450 Assays and qHTS
J Biomol Screen, June 1, 2009; 14(5): 538 - 546.
[Abstract] [PDF]


Home page
J Biomol ScreenHome page
S. L. Matson, M. Chatterjee, D. A. Stock, J. E. Leet, E. A. Dumas, C. D. Ferrante, W. E. Monahan, L. S. Cook, J. Watson, N. J. Cloutier, et al.
Best Practices in Compound Management for Preserving Compound Integrity and Accurately Providing Samples for Assays
J Biomol Screen, June 1, 2009; 14(5): 476 - 484.
[Abstract] [PDF]